Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Receivables: 2013-2025

Historic Receivables for Ptc Therapeutics (PTCT) over the last 11 years, with Sep 2025 value amounting to $203.1 million.

  • Ptc Therapeutics' Receivables rose 1.55% to $203.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $768.3 million, marking a year-over-year increase of 2.90%. This contributed to the annual value of $158.6 million for FY2024, which is 1.53% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Receivables stood at $203.1 million, which was up 3.54% from $196.1 million recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Receivables peaked at $210.5 million during Q1 2025, and registered a low of $78.8 million during Q2 2021.
  • Its 3-year average for Receivables is $187.4 million, with a median of $196.1 million in 2025.
  • Its Receivables has fluctuated over the past 5 years, first soared by 78.86% in 2021, then fell by 1.69% in 2024.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Receivables stood at $110.5 million in 2021, then surged by 40.88% to $155.6 million in 2022, then grew by 3.48% to $161.0 million in 2023, then decreased by 1.53% to $158.6 million in 2024, then grew by 1.55% to $203.1 million in 2025.
  • Its Receivables stands at $203.1 million for Q3 2025, versus $196.1 million for Q2 2025 and $210.5 million for Q1 2025.